132 related articles for article (PubMed ID: 37438082)
1. [Analysis the effect of cytokine-induced killer cells combined with mFOLFOX6 regimen in chemotherapy for advanced colorectal cancer].
Wang JJ; Lyu JD; Peng X
Zhonghua Yi Xue Za Zhi; 2023 Jul; 103(26):2000-2005. PubMed ID: 37438082
[No Abstract] [Full Text] [Related]
2. Clinical effects of autologous dendritic cells combined with cytokine-induced killer cells followed by chemotherapy in treating patients with advanced colorectal cancer: a prospective study.
Lin T; Song C; Chuo DY; Zhang H; Zhao J
Tumour Biol; 2016 Apr; 37(4):4367-72. PubMed ID: 26499782
[TBL] [Abstract][Full Text] [Related]
3. [A pilot study of chemotherapy combined with intraperitoneal perfusion of cytokine-induced killer cells for advanced gastric cancer patients with ascites].
Wang ZM; Zhuang RY; Chen Y; Feng Y; Li Q; Liu TS
Zhonghua Wei Chang Wai Ke Za Zhi; 2013 Jan; 16(1):28-31. PubMed ID: 23355235
[TBL] [Abstract][Full Text] [Related]
4. [Clinical study of autologous cytokine-induced killer cells combined with XELOX regimen in the treatment of senile advanced gastric cancer].
Cui Y; Bai B; Wen Y; Kuang S
Zhonghua Wei Chang Wai Ke Za Zhi; 2014 Jul; 17(7):698-701. PubMed ID: 25070452
[TBL] [Abstract][Full Text] [Related]
5. Cytokine-induced killer cells/dendritic cells-cytokine induced killer cells immunotherapy combined with chemotherapy for treatment of colorectal cancer in China: a meta-analysis of 29 trials involving 2,610 patients.
Zhang L; Mu Y; Zhang A; Xie J; Chen S; Xu F; Wang W; Zhang Y; Ren S; Zhou C
Oncotarget; 2017 Jul; 8(28):45164-45177. PubMed ID: 28404886
[TBL] [Abstract][Full Text] [Related]
6. Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial.
Venook AP; Niedzwiecki D; Lenz HJ; Innocenti F; Fruth B; Meyerhardt JA; Schrag D; Greene C; O'Neil BH; Atkins JN; Berry S; Polite BN; O'Reilly EM; Goldberg RM; Hochster HS; Schilsky RL; Bertagnolli MM; El-Khoueiry AB; Watson P; Benson AB; Mulkerin DL; Mayer RJ; Blanke C
JAMA; 2017 Jun; 317(23):2392-2401. PubMed ID: 28632865
[TBL] [Abstract][Full Text] [Related]
7. Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial.
Yamada Y; Takahari D; Matsumoto H; Baba H; Nakamura M; Yoshida K; Yoshida M; Iwamoto S; Shimada K; Komatsu Y; Sasaki Y; Satoh T; Takahashi K; Mishima H; Muro K; Watanabe M; Sakata Y; Morita S; Shimada Y; Sugihara K
Lancet Oncol; 2013 Dec; 14(13):1278-86. PubMed ID: 24225157
[TBL] [Abstract][Full Text] [Related]
8. Clinical efficacy analysis of Dendritic Cell-Cytokine Induced Killer Cell Immunotherapy Combined with Paclitaxel-Cisplatin Chemotherapy in patients with Advanced Ovarian Cancer.
Gao Y; Hao Y; Jia Y
J BUON; 2021; 26(2):553-560. PubMed ID: 34077005
[TBL] [Abstract][Full Text] [Related]
9. mFOLFOX6 Plus Panitumumab Versus 5-FU/LV Plus Panitumumab After Six Cycles of Frontline mFOLFOX6 Plus Panitumumab: A Randomized Phase II Study of Patients With Unresectable or Advanced/Recurrent, RAS Wild-type Colorectal Carcinoma (SAPPHIRE)-Study Design and Rationale.
Nagata N; Mishima H; Kurosawa S; Oba K; Sakamoto J
Clin Colorectal Cancer; 2017 Jun; 16(2):154-157.e1. PubMed ID: 28284575
[TBL] [Abstract][Full Text] [Related]
10. Analysis of the Clinical Efficacy of Dendritic Cell -cytokine Induced Killer Cell-based Adoptive Immunotherapy for Colorectal Cancer.
Xu H; Qin W; Feng H; Song D; Yang X; Zhang J
Immunol Invest; 2021 Aug; 50(6):622-633. PubMed ID: 32718264
[No Abstract] [Full Text] [Related]
11. Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial.
Cremolini C; Antoniotti C; Rossini D; Lonardi S; Loupakis F; Pietrantonio F; Bordonaro R; Latiano TP; Tamburini E; Santini D; Passardi A; Marmorino F; Grande R; Aprile G; Zaniboni A; Murgioni S; Granetto C; Buonadonna A; Moretto R; Corallo S; Cordio S; Antonuzzo L; Tomasello G; Masi G; Ronzoni M; Di Donato S; Carlomagno C; Clavarezza M; Ritorto G; Mambrini A; Roselli M; Cupini S; Mammoliti S; Fenocchio E; Corgna E; Zagonel V; Fontanini G; Ugolini C; Boni L; Falcone A;
Lancet Oncol; 2020 Apr; 21(4):497-507. PubMed ID: 32164906
[TBL] [Abstract][Full Text] [Related]
12. [Autologous cytokine-induced killer cells therapy on the quality of life of patients with breast cancer after adjuvant chemotherapy: a prospective study].
Liang XF; Ma DC; Ding ZY; Liu ZZ; Guo F; Liu L; Yu HY; Han YL; Xie XD
Zhonghua Zhong Liu Za Zhi; 2013 Oct; 35(10):764-8. PubMed ID: 24378099
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic outcomes of autologous CIK cells as a maintenance therapy in the treatment of lung cancer patients: A retrospective study.
Luo H; Gong L; Zhu B; Huang Y; Tang C; Yu S; Yang Z; Zhou X
Biomed Pharmacother; 2016 Dec; 84():987-993. PubMed ID: 27764762
[TBL] [Abstract][Full Text] [Related]
14. Prospective study of chemotherapy in combination with cytokine-induced killer cells in patients suffering from advanced non-small cell lung cancer.
Wu C; Jiang J; Shi L; Xu N
Anticancer Res; 2008; 28(6B):3997-4002. PubMed ID: 19192663
[TBL] [Abstract][Full Text] [Related]
15. Autologous Cytokine-Induced Killer Cells Improves Overall Survival of Metastatic Colorectal Cancer Patients: Results From a Phase II Clinical Trial.
Zhao H; Wang Y; Yu J; Wei F; Cao S; Zhang X; Dong N; Li H; Ren X
Clin Colorectal Cancer; 2016 Sep; 15(3):228-35. PubMed ID: 27052743
[TBL] [Abstract][Full Text] [Related]
16. Chemotherapy with or without autologous cytokine-induced killer cell transfusion as the first-line treatment for stage IV gastrointestinal cancer: a phase II clinical trial.
Xu YC; Xu Q; Li JJ; Gu XF; Lin XL; Sun L; Lu HM; Tang L; Ma Y; Lu Z; Wang HX
J Cancer Res Clin Oncol; 2016 Jun; 142(6):1315-23. PubMed ID: 26941189
[TBL] [Abstract][Full Text] [Related]
17. Effect of maintenance therapy with dendritic cells: cytokine-induced killer cells in patients with advanced non-small cell lung cancer.
Shi SB; Ma TH; Li CH; Tang XY
Tumori; 2012; 98(3):314-9. PubMed ID: 22825506
[TBL] [Abstract][Full Text] [Related]
18. Immunomodulatory effect of DC/CIK combined with chemotherapy in multiple myeloma and the clinical efficacy.
Zhao X; Ji CY; Liu GQ; Ma DX; Ding HF; Xu M; Xing J
Int J Clin Exp Pathol; 2015; 8(10):13146-55. PubMed ID: 26722513
[TBL] [Abstract][Full Text] [Related]
19. [Efficacy of Autologous DC-CIK Cells Combined with Other Immune Cells in the Treatment of Hematological Malignancies -Retrospective Study].
Liu HS; Shi J; Liu HB; Ma TT; Li XR; Zhang M
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Jun; 27(3):983-990. PubMed ID: 31204965
[TBL] [Abstract][Full Text] [Related]
20. SAPPHIRE: a randomised phase II study of planned discontinuation or continuous treatment of oxaliplatin after six cycles of modified FOLFOX6 plus panitumumab in patients with colorectal cancer.
Munemoto Y; Nakamura M; Takahashi M; Kotaka M; Kuroda H; Kato T; Minagawa N; Noura S; Fukunaga M; Kuramochi H; Touyama T; Takahashi T; Miwa K; Satake H; Kurosawa S; Miura T; Mishima H; Sakamoto J; Oba K; Nagata N
Eur J Cancer; 2019 Sep; 119():158-167. PubMed ID: 31445198
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
